Posttransplant metabolic syndrome in children and adolescents after liver transplantation: A systematic review

Emily Rothbaum Perito, Audrey Lau, Sue Rhee, John P. Roberts, Philip Rosenthal – 29 May 2012 – During long‐term follow‐up, 18% to 67% of pediatric liver transplant recipients are overweight or obese, with rates varying by age and pretransplant weight status. A similar prevalence of posttransplant obesity has been seen in adults. Adults also develop posttransplant metabolic syndrome and, consequently, cardiovascular disease at rates that exceed the rates in age‐ and sex‐matched populations.

Chemoprophylaxis with isoniazid in liver transplant recipients

Emilio Fábrega, Blanca Sampedro, Joaquín Cabezas, Fernando Casafont, Miguel Ángel Mieses, Irene Moraleja, Javier Crespo, Fernando Pons‐Romero – 29 May 2012 – A patient receiving a liver graft needs to be treated with immunosuppressive drugs to avoid rejection. These kinds of drugs predispose the patient to the reactivation of latent infections such as tuberculosis (TB). Therefore, it is necessary to establish treatment regimens to prevent this.

Comparative effectiveness of donation after cardiac death versus donation after brain death liver transplantation: Recognizing who can benefit

Colleen L. Jay, Anton I. Skaro, Daniela P. Ladner, Edward Wang, Vadim Lyuksemburg, Yaojen Chang, Hongmei Xu, Sandhya Talakokkla, Neehar Parikh, Jane L. Holl, Gordon B. Hazen, Michael M. Abecassis – 29 May 2012 – Due to organ scarcity and wait‐list mortality, transplantation of donation after cardiac death (DCD) livers has increased. However, the group of patients benefiting from DCD liver transplantation is unknown. We studied the comparative effectiveness of DCD versus donation after brain death (DBD) liver transplantation.

Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance

Banff Working Group on Liver Allograft Pathology, Anthony Demetris – 29 May 2012 – Obstacles to morbidity‐free long‐term survival after liver transplantation (LT) include complications of immunosuppression (IS), recurrence of the original disease and malignancies, and unexplained chronic hepatitis and graft fibrosis. Many programs attempt to minimize chronic exposure to IS by reducing dosages and stopping steroids. A few programs have successfully weaned a highly select group of recipients from all IS without apparent adverse consequences, but long‐term follow‐up is limited.

Subscribe to